Clarity AD could yield a range of scenarios, and Biogen isn’t ruling out dredging secondary endpoints if the primary fails.
The group buys out its partner Genetx, but inconsistent data spook investors.
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.